WNK1 Inhibitors
The chemical class of WNK1 inhibitors mainly consists of compounds that indirectly affect WNK1 by targeting pathways related to electrolyte balance, blood pressure regulation, and fluid homeostasis. These inhibitors influence the physiological processes and signaling pathways associated with WNK1's function, rather than directly inhibiting the kinase itself.
Compounds such as Spironolactone, Eplerenone, Amiloride, Hydrochlorothiazide, Furosemide, and Metolazone are diuretics that affect electrolyte and fluid balance. By altering sodium and potassium levels, these compounds can indirectly modulate the activity of WNK1, which plays a critical role in regulating these ions' homeostasis. The changes in electrolyte balance and fluid volume can impact the signaling pathways in which WNK1 is involved, thereby affecting its regulatory functions. Additionally, compounds like Losartan, Candesartan, Lisinopril, Enalapril, and Valsartan, which are used in the management of hypertension, can indirectly influence WNK1 activity. These drugs modulate the renin-angiotensin-aldosterone system (RAAS), which is intricately linked to electrolyte balance and blood pressure regulation. By affecting this system, these inhibitors can indirectly impact WNK1's role in these processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone, a potassium-sparing diuretic, might indirectly affect WNK1's role in electrolyte balance and blood pressure. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
Eplerenone, another potassium-sparing diuretic, could influence WNK1 activity indirectly through its effects on mineral balance. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Amiloride, a diuretic affecting sodium transport, might indirectly modulate WNK1's role in sodium and potassium homeostasis. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $55.00 $240.00 $333.00 $562.00 $988.00 | ||
Hydrochlorothiazide, a diuretic, can influence electrolyte balance, potentially affecting WNK1's regulatory functions. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor blocker, might affect WNK1 indirectly by modulating blood pressure and electrolyte balance. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, another angiotensin receptor blocker, could influence WNK1 activity through its effects on vascular tone. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide, a loop diuretic, might indirectly modulate WNK1 activity due to its effects on sodium and chloride transport. | ||||||
Torsemide | 56211-40-6 | sc-213059 | 10 mg | $260.00 | ||
Torasemide, a loop diuretic, can influence WNK1 indirectly through its diuretic and antihypertensive properties. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Valsartan, an angiotensin II receptor antagonist, might affect WNK1 activity indirectly through blood pressure regulation. | ||||||
Metolazone | 17560-51-9 | sc-211900 | 100 mg | $228.00 | ||
Metolazone, a thiazide-like diuretic, could indirectly influence WNK1's role in sodium and potassium balance. | ||||||